Pharmagreen Biotech Inc.

OTCPK:PHBI Stock Report

Market Cap: US$1.1m

Pharmagreen Biotech Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Peter Wojcik

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.9yrs
CEO ownership5.3%
Management average tenureno data
Board average tenureno data

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Peter Wojcik's remuneration changed compared to Pharmagreen Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$1m

Jun 30 2024n/an/a

-US$404k

Mar 31 2024n/an/a

-US$524k

Dec 31 2023n/an/a

-US$674k

Sep 30 2023n/an/a

-US$569k

Jun 30 2023n/an/a

-US$501k

Mar 31 2023n/an/a

-US$86k

Dec 31 2022n/an/a

-US$934k

Sep 30 2022US$94kUS$94k

-US$875k

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

-US$2m

Dec 31 2021n/an/a

-US$4m

Sep 30 2021US$95kUS$95k

-US$5m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020n/an/a

-US$3m

Sep 30 2020US$93kUS$93k

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$491k

Dec 31 2019n/an/a

-US$581k

Sep 30 2019US$90kUS$90k

-US$768k

Jun 30 2019n/an/a

-US$413k

Mar 31 2019n/an/a

-US$1m

Dec 31 2018n/an/a

-US$1m

Sep 30 2018US$102kn/a

-US$742k

Compensation vs Market: Insufficient data to establish whether Peter's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

CEO

Peter Wojcik (52 yo)

6.9yrs

Tenure

US$93,964

Compensation

Mr. Peter Wojcik, B.A. Adv., serves as Chief Executive Officer and Director at Pharmagreen Biotech Inc., since February 2, 2018 and serves as its President, Secretary and Treasurer since February 21, 2018....

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 19:00
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmagreen Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution